Physician profile
Samir Hasan Ebeid
NPI 1871695429
$2,194.33
in general payments reported to CMS, 2019-2025
12 companies · $91.14 in 2025
The $91.14 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2021: $72.58 · 2022: $45.49 · 2023: $179 · 2024: $34.48 · 2025: $91.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,674.22 | 2019 | |
| Merck Sharp & Dohme LLC | $105.52 | 2021-2023 | Vaxneuvance, Proquad, Rotateq |
| Supernus Pharmaceuticals, INC. | $79.23 | 2021-2023 | Qelbree |
| Pfizer INC. | $68.34 | 2019-2025 | |
| Glaxosmithkline, LLC. | $62.83 | 2021-2025 | Bexsero |
| Ironshore Pharmaceuticals INC. | $58.84 | 2021-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $41.45 | 2025 | Jornay Pm |
| Shire North American Group INC | $39.07 | 2019 | |
| Seqirus USA INC | $19.04 | 2023 | Flucelvax Quadrivalent |
| Sobi, INC | $15.68 | 2019 | |
| Tris Pharma INC | $15.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Ebeid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.